11.10.2012 - French chromatography specialist Novasep will create the world's largest chromatography plant for the pharmaceutical industry.
French bio-chromatography provider Novasep S.A. is set to build the world’s largest chromatography plant in Europe at its Mourenx site, for purification of pharmaceuticals. The company, which combined its technologies in large scale chromatography with German stationary phase provider instrAction two years ago, said the plant will be operational and validated within 18 months. Both the development of an advanced purification process and the plant expansion within the challenging timescale are results of the sharp increase in the projected demand for a large volume, highly purified API. New analyses from Frost & Sullivan predict the monoclonal antibody market in Europe to grow from US$19bn in 2011 to US$42.4bn in 2018 alone.
The €30m investment follows two other significant global investments in 2012: the opening of a new 2,000sqm facility in Shanghai and a €3m investment to expand the Highly Potent API (HPAPI) manufacturing capabilities in Le Mans. "Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third, and largest global plant expansion in 2012," said Patrick Glaser, President and CEO of Novasep. The investment was supported by contributions of local authorities of Lacq, the General Council of Pyrénées Atlantiques, the Regional Council of Aquitaine, the Economic Development Bureau, DIRECCTE Aquitaine, the Prefecture of Pyrénées Atlantiques, the Total Group, and OSEO, France's innovation agency.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more